Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Finished Goods for 3 consecutive years, with $12.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Finished Goods fell 15.85% year-over-year to $12.9 million, compared with a TTM value of $12.9 million through Dec 2023, down 15.85%, and an annual FY2023 reading of $12.9 million, down 15.85% over the prior year.
  • Finished Goods was $12.9 million for Q4 2023 at Kiniksa Pharmaceuticals International, up from $12.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $19.9 million in Q2 2022 and bottomed at $1.4 million in Q3 2021.
  • Average Finished Goods over 3 years is $10.4 million, with a median of $12.5 million recorded in 2023.
  • The sharpest move saw Finished Goods surged 927.48% in 2022, then decreased 24.22% in 2023.
  • Year by year, Finished Goods stood at $3.7 million in 2021, then skyrocketed by 315.97% to $15.3 million in 2022, then fell by 15.85% to $12.9 million in 2023.
  • Business Quant data shows Finished Goods for KNSA at $12.9 million in Q4 2023, $12.2 million in Q3 2023, and $17.3 million in Q2 2023.